Table 3.
Clinical characteristics and levels of haemostatic variables in patients with active and inactive AAV
| Characteristic | Active AAV (n = 19) | Inactive AAV (n = 15) | P-value |
|---|---|---|---|
| Age | 60.5 (15.5) | 59.1 (15.3) | ns |
| Sex, male/female | 10/9 | 6/9 | |
| GPA/MPA | 12 GPA/7 MPA | 15 GPA/0 MPA | |
| BVAS | 14 (9.3) | 0 | |
| Plasma creatinine, mg/day | 131 (89.4) | 89 (24.7) | 0.045 |
| Prednisolone, mg/day, mean (range) | 32.9 (0–80) | 6.2 (0–20) | 0.011 |
| Methylprednisolone | 2 | 0 | |
| DMARD, any | 6 | 12 | 0.15 |
| MTX | 4 (21.1) | 5 (33.3) | 0.46 |
| AZA | 0 (0) | 4 (26.7) | 0.03 |
| MMF | 2 (10.5) | 3 (20) | 0.63 |
| ASA | 0 (0) | 2 (13.3) | 0.19 |
| Warfarin, ongoing | 0 (0) | 0 (0) | 1 |
| Antihypertensive treatment (any) | 9 (47.4) | 8 (53.3) | 1.0 |
| ACEi | 1 (5.3) | 4 (26.7) | 0.15 |
| ARB | 3 (15.8) | 5 (33.3) | 0.42 |
| β-Blockers | 5 (26.3) | 7 (46.7) | 0.29 |
| Diuretics | 2 (10.5) | 1 (6.7) | 1.0 |
| Statins | 3 (15.8) | 2 (13.3) | 1.0 |
| Malignancy, ever | 1a | 0 | |
| Haemostasis markers | |||
| OCP (Abs-sum) | 27.9 (1.5) | 24.7 (1.5) | 0.06 |
| OHP (Abs-sum) | 23.2 (1.3) | 17.4 (1.4) | <0.01 |
| OFP (%) | 16.7 (2.0) | 30.2 (2.3) | <0.0001 |
| ETP (mA) | 104.9 (2.5) | 93.6 (2.7) | 0.019 |
Variables are presented as the mean (s.e.) unless stated otherwise. P-values in bold remain significant after Bonferroni correction for multiple testing. aPrevious breast cancer. Abs-sum: Sum of absorbance values; ACEi: angotensin-converting enzyme inhibitor; ARB: angiotensin receptor II blocker; BVAS: Birmingham Vasculitis Activity Score; ETP: endogenous thrombin potential; GPA: granulomatosis with polyangitis; MPA: microscopic polyangitis; ns: not significant; OCP: overall coagulation potential; OFP: overall fibrinolytic potential; OHP: overall haemostatic potential.